



## Clinical trial results:

**Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects**

### Summary

EudraCT number	2017-000648-16
Trial protocol	DE
Global end of trial date	27 October 2017

### Results information

Result version number	v1 (current)
This version publication date	18 August 2018
First version publication date	18 August 2018

### Trial information

#### Trial identification

Sponsor protocol code	BAY59-7939/19365
-----------------------	------------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, D-51368 Leverkusen, Germany,
Public contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 October 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 October 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the trial was to establish bioequivalence with respect to area under concentration versus time curve from zero to infinity after single dose administration (AUC), AUC from time zero to the last data point (AUC[0-tlast]) and maximum observed drug concentration (Cmax) of 10 milligrams (mg) granules for oral suspension versus 10 mg tablets rivaroxaban (BAY59-7939, Xarelto) when administered as single oral dose under fasting conditions.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 July 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 30
Worldwide total number of subjects	30
EEA total number of subjects	30

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	30
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Study was conducted at one study center in Germany, between 05 July 2017 (first subject first visit) and 30 August 2017 (last subject last visit).

### Pre-assignment

Screening details:

Overall, 66 subjects were screened, of these 36 subjects were screen failures: 3 subjects withdrew consent, 1 subject was not included due to physician's decision and 32 subjects failed screening. A total of 30 subjects were randomized to treatment and all subjects completed the study.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment A-B

Arm description:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Arm type	Experimental
Investigational medicinal product name	Rivaroxaban
Investigational medicinal product code	BAY59-7939
Other name	Xarelto
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A).

Investigational medicinal product name	Rivaroxaban
Investigational medicinal product code	BAY59-7939
Other name	Xarelto
Pharmaceutical forms	Granules for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B).

<b>Arm title</b>	Treatment B-A
------------------	---------------

Arm description:

Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Rivaroxaban
Investigational medicinal product code	BAY59-7939
Other name	Xarelto
Pharmaceutical forms	Granules for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B).

Investigational medicinal product name	Rivaroxaban
Investigational medicinal product code	BAY59-7939
Other name	Xarelto
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A).

<b>Number of subjects in period 1</b>	Treatment A-B	Treatment B-A
Started	15	15
Completed	15	15

## Baseline characteristics

### Reporting groups

Reporting group title	Treatment A-B
-----------------------	---------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Reporting group title	Treatment B-A
-----------------------	---------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Reporting group values	Treatment A-B	Treatment B-A	Total
Number of subjects	15	15	30
Age Categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	35.2 ± 11.5	42.9 ± 11.2	-
Gender Categorical Units: Subjects			
Male	15	15	30

## End points

### End points reporting groups

Reporting group title	Treatment A-B
-----------------------	---------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Reporting group title	Treatment B-A
-----------------------	---------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out period of 7 days was maintained between the treatments.

Subject analysis set title	Safety Analysis Set (SAF)
----------------------------	---------------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

SAF included all subjects who received at least one dose of the study medication (N= 30).

Subject analysis set title	Pharmacokinetic Analysis Set (PKS)
----------------------------	------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

PKS included all subjects who completed all treatment periods, and for whom valid sets of pharmacokinetic samples were taken (N= 30).

Subject analysis set title	10 mg Rivaroxaban tablet
----------------------------	--------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 during any of the intervention periods (N= 30).

Subject analysis set title	10 mg Rivaroxaban oral suspension
----------------------------	-----------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Subjects received a single oral dose of 10 mg rivaroxaban granules for oral suspension in the fasted state on Day 1 during any of the intervention periods (N = 30).

### Primary: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Rivaroxaban in Plasma After Single Dose Administration

End point title	Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Rivaroxaban in Plasma After Single Dose Administration
-----------------	--

End point description:

Area under the concentration versus time curve from zero to infinity of rivaroxaban in plasma after single dose administration was measured. Geometric mean and geometric coefficient of variation were reported.

End point type	Primary
----------------	---------

End point timeframe:

pre dose up to 72 hours post dose

End point values	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	30 <sup>[1]</sup>	30 <sup>[2]</sup>		
Units: microgram*hour per liter (mcg*h/L)				
geometric mean (geometric coefficient of variation)	1010 ( $\pm$ 29.2)	1040 ( $\pm$ 27.1)		

Notes:

[1] - PKS

[2] - PKS

## Statistical analyses

Statistical analysis title	Statistical analysis 1
----------------------------	------------------------

Statistical analysis description:

Logarithms of the AUC were analyzed using analysis of variance (ANOVA) including sequence, subject (sequence), period, treatment effects. Based on these analyses point estimates (Least squares [LS] Mean) and confirmatory 90 percent confidence intervals for treatment ratio: 10 mg granules for oral suspension/tablet were calculated by re-transformation of the logarithmic results given by ANOVA. Database auto-calculates total number of subjects erroneously, analyzed number of subjects was 30.

Comparison groups	10 mg Rivaroxaban tablet v 10 mg Rivaroxaban oral suspension
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS mean
Point estimate	1.0267
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.9841
upper limit	1.0712

## Primary: Area Under the Concentration Versus Time Curve From Time Zero to the Last Data Point Greater Than (>) Lower Limit Of Quantification (LLOQ) (AUC[0-tlast]) of Rivaroxaban in Plasma After Single Dose Administration

End point title	Area Under the Concentration Versus Time Curve From Time Zero to the Last Data Point Greater Than (>) Lower Limit Of Quantification (LLOQ) (AUC[0-tlast]) of Rivaroxaban in Plasma After Single Dose Administration
-----------------	---

End point description:

Area under the concentration versus time curve from time zero to the last data point greater than (>) lower limit of quantification of rivaroxaban in plasma after single dose administration was measured. Geometric Mean and percentage of geometric coefficient of variation were reported.

End point type	Primary
----------------	---------

End point timeframe:

pre dose up to 72 hours post dose



End point values	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	30 <sup>[3]</sup>	30 <sup>[4]</sup>		
Units: microgram*hour per liter (mcg*L)				
geometric mean (geometric coefficient of variation)	989 (± 29.6)	1010 (± 27.6)		

Notes:

[3] - PKS

[4] - PKS

## Statistical analyses

Statistical analysis title	Statistical analysis 1
----------------------------	------------------------

Statistical analysis description:

Logarithms of the AUC(0-tlast) were analyzed using ANOVA including sequence, subject (sequence), period, treatment effects. Based on these analyses point estimates (LS mean) and confirmatory 90 percent confidence intervals for treatment ratio: 10 mg granules for oral suspension/tablet were calculated by re-transformation of the logarithmic results given by ANOVA. Database auto-calculates total number of subjects erroneously, analyzed number of subjects was 30.

Comparison groups	10 mg Rivaroxaban tablet v 10 mg Rivaroxaban oral suspension
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS mean
Point estimate	1.0261
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.9805
upper limit	1.0738

## Primary: Maximum Observed Drug Concentration (Cmax) of Rivaroxaban in Plasma After Single Dose Administration

End point title	Maximum Observed Drug Concentration (Cmax) of Rivaroxaban in Plasma After Single Dose Administration
-----------------	--

End point description:

Maximum observed drug concentration of rivaroxaban in plasma after single dose administration was measured. Geometric mean and percentage coefficient of variation were reported.

End point type	Primary
----------------	---------

End point timeframe:

pre dose up to 72 hours post dose

End point values	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	30 <sup>[5]</sup>	30 <sup>[6]</sup>		
Units: microgram per liter (mcg/L)				
geometric mean (geometric coefficient of variation)	127 ( $\pm$ 27.6)	143 ( $\pm$ 23.1)		

Notes:

[5] - PKS

[6] - PKS

## Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Logarithms of the C <sub>max</sub> were analyzed using ANOVA including sequence, subject (sequence), period, treatment effects. Based on these analyses point estimates (LS mean) and confirmatory 90 percent confidence intervals for treatment ratio: 10 mg granules for oral suspension/tablet were calculated by re-transformation of the logarithmic results given by ANOVA. Database auto-calculates total number of subjects erroneously, analyzed number of subjects was 30.	
Comparison groups	10 mg Rivaroxaban tablet v 10 mg Rivaroxaban oral suspension
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS mean
Point estimate	1.1283
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.04
upper limit	1.224

## Secondary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

End point title	Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
End point description:	
An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. AEs that started or worsened after first administration of study medication up to 14 days after end of treatment with study medication were considered to be treatment emergent (TE).	
End point type	Secondary
End point timeframe:	
from start of study drug administration up to 14 days after last study drug administration	

<b>End point values</b>	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	30 <sup>[7]</sup>	30 <sup>[8]</sup>		
Units: count of subjects	2	4		

Notes:

[7] - SAF

[8] - SAF

### **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the start of study drug administration until 14 days after last study drug administration

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

### Reporting groups

Reporting group title	10 mg Rivaroxaban tablet
-----------------------	--------------------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 during any of the intervention periods.

Reporting group title	10 mg Rivaroxaban oral suspension
-----------------------	-----------------------------------

Reporting group description:

Subjects received a single oral dose of 10 mg rivaroxaban granules for oral suspension in the fasted state on Day 1 during any of the intervention periods.

Serious adverse events	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	10 mg Rivaroxaban tablet	10 mg Rivaroxaban oral suspension	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 30 (6.67%)	4 / 30 (13.33%)	
Injury, poisoning and procedural complications			
Arthropod sting			
subjects affected / exposed	1 / 30 (3.33%)	0 / 30 (0.00%)	
occurrences (all)	1	0	
Contusion			
subjects affected / exposed	0 / 30 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	1 / 30 (3.33%) 1	
Musculoskeletal and connective tissue disorders Bursitis subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 30 (3.33%) 1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Occurrence of "±" in relation with geometric CV is auto generated. Decimal places were automatically truncated if last decimals is equals to zero.
--

Notes: